cyrilzakka/clinical-trials huggingface dataset:
Irreversible Electroporation for Treatment of Solid Abdominal Tumors

Irreversible electroporation (IRE) is a novel non-thermal ablation modality with promise for revolutionizing the treatment for local solid tumors.

With the growing demand for alternative and less invasive treatments for localized tumors, the investigators have seen the development and investigation of several tissue ablation modalities, including radiofrequency ablation (RFA), microwave ablation, and cryoablation. Although these modalities have been efficacious, they have some disadvantages owing to their reliance on thermal energy for creating cell death.

Irreversible electroporation is novel in that it does not use thermal energy, but electrical energy to produce focused cell death while sparing the normal extracellular matrix, nearby vessels, and structures, while allowing for rapid normal tissue regrowth.

Unlike thermal ablation modalities, Irreversible electroporation does not require significant consideration for dissipation of thermal energy, or heat sink, and has less complications relating to damage of normal soft tissue, eliminating a major cause of treatment failure.

Irreversible electroporation is a novel minimally invasive tumor/tissue ablation technique that can be used under guidance of ultrasound (US) or computed tomography (CT), without inducing thermal damaging effects, and with preservation of the surrounding vital structures such as vessels, bile ducts, urethra, and nerves which remain intact to function normally, even in locally advanced tumors. The technique depends upon inducing apoptotic non-necrotic cell death in short procedure time.

It has the advantage of allowing quick tissue regeneration. Irreversible electroporation treatment time is significantly shorter than traditional thermal ablation modalities, usually in few minutes range, and allows for treating considerably larger lesions than thermal ablation modalities.

Eligibility Criteria:
Inclusion Criteria:

* Patients with unresectable solid abdominal tumors (hepatic, pancreatic, porta hepatis,...).
* The mass measures less than 4 cm.
* Associated with no or oligo metastatic lesions

Exclusion Criteria:

* Patients with cardiac arrhythmia and pacemaker.
* Patients unfit for general anesthesia.
* The lesion size is larger than 4 cm.
Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

The purpose of this study is to determine if the use of inhaled beclomethasone after a community-acquired respiratory viral infection in a lung transplant recipient decreases the risk of the subsequent development of chronic lung allograft dysfunction.

Community-acquired respiratory viral (CARV) infections after lung transplantation are associated with an increased risk for the development of chronic lung allograft dysfunction (CLAD) after lung transplantation. The exact mechanisms whereby CARV infections increase this risk are unknown. We propose that viral infection results in airway epithelial cell injury and the expression of injury-response genes that provide signals that initiate immunologic and non-immunologic pathways that result in the airway remodeling characteristic of obliterative bronchiolitis, the predominant pathology of CLAD. Systemic and inhaled corticosteroids are frequently used as anti-inflammatory agents to treat the peribronchiolar inflammation seen in viral bronchiolitis. Beneficial effects from corticosteroids have been reported, but this has not been demonstrated in lung transplant recipients. The aim of this single center, randomized, double blind, placebo controlled study is to evaluate the short and long term effects of a 6 month course of inhaled beclomethasone on adult lung transplant recipients with CARV infection.

Eligibility Criteria:
Inclusion Criteria:

* Adult (≥ 18 years old)
* Single, bilateral, or heart-lung transplant recipient
* Confirmed infection with a community-acquired respiratory virus including: adenovirus, coronavirus, influenza A or B, respiratory syncytial virus (RSV), parainfluenza virus (PiV), human metapneumovirus (hMPV), and rhinovirus
* At least 6 months post-transplant, with completion of 6 month bronchoscopy if indicated
* Able and willing to give written informed consent and comply with study procedures (e.g. testing, treatment)

Exclusion Criteria:

* BOS Stage 3
* Requirement for mechanical ventilation at study entry
* Use of inhaled steroids at the time of CARV infection
* Any condition that in the investigator's opinion would preclude the patient's participation in a clinical trial
* Lack of available spirometric data to establish a baseline forced expiratory volume in 1 second and/or forced vital capacity
* Pregnancy
* Current participation in another interventional clinical trial
Subaxial Cervical Traumatic Injuries

The aim of this study is to assess the mid-term outcomes of treating subaxial cervical traumatic injury cases admitted to the Trauma Unit of Assiut University Hospital.

Injuries to the subaxial cervical spine can be bony, discoligamentous or a combination of both. Cervical spine trauma is common resulting from high energy trauma such as falling from height and motor vehicle accident . The subaxial cervical spine is a common site of cervical injury with more than 50 % of injuries being located between C5 and C7 MRI is superior to CT scans for evaluating the spinal cord, nerve roots, disc, and ligamentous structures in the cervical spine There are a couple of classification systems that have been devised The first is the Subaxial Injury Classification System (SLIC). This classification stratifies the type of fracture, the competency of the DLC, and the patient's neurologic status with numerical values to determine the course of treatment.

A second classification system is the AO Spine Subaxial Cervical Spine Injury Classification. The AO Spine SCICS classifies injuries based on 4 parameters: injury morphology, facet involvement, neurological status, and case-specific modifiers Patients with fractures deemed unstable or neurologic compromise should undergo decompression and stabilization. Intervention within 24 hours of injury leads to better improvement in ASIA scores .

Although we receive and treat a large number of patients with various subaxial cervical traumatic injuries in Assiut University Hospital each year, there is uncertainty about the midterm outcome of the treatment we provide.

In this study, The investigators will assess the mid-term outcomes of all patients with subaxial cervical traumatic injuries who complete a minimum one year follow up regardless of the neurological status or treatment type used.

Eligibility Criteria:
Inclusion Criteria:

* All patients presenting with subaxial cervical spine traumatic injuries with and without cervical cord injury who complete a minimum of one year follow up

Exclusion Criteria:

* Patients who refuse to participate in the study Patients with pathological fractures
A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule

This is a regulatory-required non-interventional pharmacovigilance study exploring the safety profile of ziprasidone HCL monohydrate 20mg, 40mg, 60mg, 80mg in the real world patient population, thus, safety (and/or efficacy) signals will be checked at every visit during the contracted study period until the maximum study end date, per the protocol, of April 2010.

All patients diagnosed with schizophrenia or acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features will be included in the study.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with schizophrenia

Exclusion Criteria:

* Patients who have known hypersensitivity to any ingredient of the product
* Patients who have had a recent acute myocardial infarction
* Patients who have uncompensated heart failure
* Patients who have conditions with a potential to increase QT interval (QT-interval prolongation or history of QT prolongation; congenital long QT syndrome; use with other drugs known to increase the QT interval; arrhythmias treated with class I and III antiarrhythmic drugs)
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

This study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS) and ISCOMATRIX™ (IMX). Reviews of safety and tolerability will be used to select the dose(s) of IMX for further studies of the octavalent HPV L1 VLP vaccine.

The study was performed in 2 staggered phases, Phase A and Phase B. In Phase A, participants were randomized to qHPV, Octavalent HPV with 15 mcg IMX/AAHS, or Octavalent HPV with 30 mcg IMX/AAHS. After the safety for Phase A was reviewed, Phase B was initiated. In Phase B, participants were randomized to qHPV, Octavalent HPV with 60 mcg IMX/AAHS or Octavalent HPV with 120 mcg IMX/AAHS.

Eligibility Criteria:
Inclusion Criteria:

* Participant is in good physical health
* Participant has had a lifetime history of 0 to 4 sexual partners
* Females between 18-to-24 years

Exclusion Criteria:

* Participant has a history of abnormal Pap test
* Participant has a history of positive test for HPV
* Participant has a history of recent or ongoing alcohol or drug abuse
* Participant is immunocompromised or has an autoimmune condition
* Participant has received immunosuppressive therapy within a year of screening
* Participant has previously received an HPV vaccine
* Participant is pregnant
* Participant has a history of external genital/vaginal warts
* Participant is currently enrolled in a clinical trial
* Participant has a history of a severe allergic reaction that required medical attention
Nurse Telephone Management of Cholesterol in Diabetes

The current project is evaluating the effect of a nurse-administered phone care in diabetes to improve access to care and healthcare delivery. The setting is a federally qualified community health center serving over 1600 diabetic patients, 80% of whom are Latino. Using our diabetes registry, we have randomly assigned 762 patients to either participate in a telephone-based, nurse-run outreach program (N=381) or to continue with usual care(N=381). Three of our registered nurses learned algorithms addressing management of cholesterol, blood pressure, kidney disease, aspirin use, eye screening, and pneumovax and influenza vaccines. The program began recruitment in September 2005 and has finished follow up in May 2007. The program initially focused only on cholesterol management utilizing national guidelines and algorithms on patients with elevated cholesterol (LDL) levels but has expanded to include glycemic and blood pressure control. We found that Registered Nurses were able and willing to provide telephone care to diabetic patients according to moderately complex algorithms and to track patient data electronically with overall job satisfaction. Overall, the nurses have expressed enthusiasm but have also experience frustrations with maintaining contact and improving motivation in patients. The impact of this program on diabetes outcomes and its cost-effectiveness is currently being analyzed with the goal of implementing this program in our institution.

This randomized, controlled trial tested the effectiveness of a nurse-run, telephone-based intervention to improve lipid control in patients with diabetes. Our patient population is predominantly low-income and Latino. Using our diabetes registry, we randomly assigned 381 patients to continue with their usual care and 381 to participate in our nurse run program. Three registered nurses learned algorithms for diabetes care. These algorithms address management of lipids, glycemic control, blood pressure, nephropathy, aspirin use, eye screening, pneumovax and influenza vaccines, obesity, and cigarette smoking. The nurses were also trained in motivational interviewing techniques and facilitation of patient self-management. The primary goal was to improve lipid control in our diabetic population. Secondary outcomes address blood pressure control, glycemic control, renal function, and medication adherence. In addition, a cost-effective analysis is being performed.

Eligibility Criteria:
Inclusion Criteria:

1. Patients included in Denver Health diabetes registry.
2. Type I and Type II diabetic patients
3. Age \>17 years old
4. Actively utilizing Westside Clinic for their primary care (at least two visits in the past year)
5. Speak either English or Spanish.

Exclusion Criteria:We sought to maximize the generalizability of the study and therefore had only minimal exclusion criteria:

1. Pregnant or lactating women
2. Patients with end-stage renal disease (creatinine \> 3.0 mg/dl)
3. Patients with a co-morbid illness with life expectancy less than 12 months, (e.g. terminal cancer or Child's Class C hepatic cirrhosis).
Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women

The aim of this study is to evaluate the gene expression of the endometrium after an endometrial biopsy in fertile women using Next Generation Sequencing of total RNA.

An endometrial biopsy is done at cycle day LH+7 and repeated in the next cycle at cycle day LH+7.

Tissue is analysed and compared for changes in gene expression profile using Seq RNA

Eligibility Criteria:
Inclusion Criteria:

* Fertile women
* Age: 18-40 years
* BMI: 18-32
* Regular menstrual cycle
* No use of hormonal contraceptives or IUD the last 3 months

Exclusion Criteria:

* Patients in need of a interpreter
* Suspected intrauterine abnormalities
* Pregnancy
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are:

* Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)?
* How does treatment duration affect perioperative safety and clinical outcomes?

Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.


Eligibility Criteria:
Inclusion Criteria:

* Non-bedridden patients aged 18-90 years;
* Histologically confirmed gastric or gastroesophageal junction adenocarcinoma by biopsy;
* Evaluated as resectable advanced gastric cancer via CT, MRI, or laparoscopic exploration;
* No prior anti-tumor treatments such as chemotherapy, radiotherapy, or immunotherapy;
* No history of other malignancies within the past 5 years;
* Received at least one cycle of PD-1 inhibitor combined with chemotherapy preoperatively, with no restrictions on the specific PD-1 inhibitor or chemotherapeutic agents;
* Underwent radical gastrectomy after neoadjuvant therapy;
* No severe underlying diseases.

Exclusion Criteria:

* Incomplete or inaccessible clinical and pathological data;
* Postoperative pathology confirming non-gastric or non-gastroesophageal junction adenocarcinoma;
* Distant metastases present prior to treatment;
* Concurrent diagnosis of other malignancies.
Effect of Sustained Natural Apophyseal Glide Combined With Strengthening Exercises of Lower Fibers of Trapezius in Patient With Unilateral Neck Pain

Neck pain is considered one of the very common cause behind musculoskeletal pain and is 4th leading cause of disability . Cervical pain is among 5 most contributing factors in causing years lived with disability.Individuals with unilateral neck pain exhibit significantly less Lower Trapezius strength than Middle and Upper Trapezius fibers .Mulligan is one of the mobilization techniques that can be applied in case of neck pain.In prolong neck pain there is a hyperactivation and shortening of upper trapezius which makes the lower trapezius weak this leads to imbalance between cervical and scapular muscles and result in impaired biomechanics. So mostly treatment focused on upper trapezius and neglecting the lower trapezius and this create increase chances of recurrency of neck pain because the imbalance remains present. So, this study aims at evaluating the effects of SNAGS combined with strengthening exercises of lower fibers of trapezius .


Eligibility Criteria:
Inclusion Criteria:

* Individuals aged 18-35 years
* Both gender
* Unilateral neck pain
* Symptoms of duration more than 3 months.
* NPRS scoring of greater than or equal to 4 points.
* Neck disability index score of 20% or above.
* Manual muscle testing : grade 3

Exclusion Criteria:

* Prior cervical and thoracic spine fractures, dislocations, or surgeries, spinal osteoporosis or infection, or whiplash.
* Any trauma or localized infection in neck region
* Psychiatric diseases such as phobia/obsession and depression
Measurement of Body Weight Using Shoe Insole Pressure Sensors

The purpose of this study is to create a dataset to help accelerate machine learning (ML) based solutions for applications such as activity recognition, detect changes in weight and predict weight of carried load. The research will further help in the development of novel machine learning-based algorithm for accurately predicting the body weight of an individual in real-time and within few ounces error margin, using sampled data from smart insole sensors.


Eligibility Criteria:
Inclusion Criteria:

* Age range of 18-70 years

Exclusion Criteria:

* Refusal to adhere to covid19 safety guidelines
Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease

Fluticasone furoate is being studied to determine whether treatment with a topical nasal steroid, in patients with existing nasal polyps , can not only improve symptoms but also suppress the recurrence of clinically significant nasal polyp obstruction and prevent surgical intervention.


Eligibility Criteria:
Inclusion Criteria:

1. Male and female patients 18-70 years of age, in general good health.
2. Current evidence of nasal polyps on physical exam. 3) Able to understand the protocol and comply with instructions. 4) Have a negative urine pregnancy test in women of childbearing potential. 5) Women of childbearing potential must be on an acceptable method of birth control or willing to remain abstinent through the duration of the study.

Exclusion Criteria:

1. Are pregnant and/or breast-feeding.
2. History of alcohol or drug abuse in the past year.
3. Signs and symptoms suggestive of fulminant bacterial sinusitis (fever \>101 F, persistent severe unilateral facial or tooth pain, facial swelling).
4. Allergies to nasal corticosteroids
5. .Other chronic significant medical illnesses 6) Maintenance oral prednisone therapy for other chronic medical conditions.

   -

   -
Evaluation of the Safety and Performance of Magneto PE Kit

This study is designed as a prospective, multi-center, multinational open labeled, single armed study to evaluate the safety and performance of the Magneto PE Kit.


Eligibility Criteria:
Inclusion Criteria:

* Clinical signs, symptoms and presentation consistent with acute PE
* PE symptom duration ≤ 14 days
* CTA evidence of PE
* RV/LV ratio ≥ 0.9
* Heart rate \<130 BPM prior to procedure
* Subject medically eligible for interventional procedure
* Age ≥ 18 and \<75 years
* Consent process is completed

Exclusion Criteria:

* Thrombolytic use within 14 days
* Known bleeding diathesis or coagulation disorder
* Any contraindication to systemic therapeutic doses of heparin or other anticoagulants
* Hemodynamic collapse at presentation
* Decompensated heart failure
* Presence of Extra-Corporeal Membrane Oxygenation.
* Major trauma ISS\> 15 within 14 days
* Cardiovascular or pulmonary surgery within last 7 days
* FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%
* Hematocrit \< 28%
* Platelets \< 100,000/µL
* Serum creatinine \> 1.8 mg/dL
* INR\>2
* Left bundle branch block
* PAP \> 70 mmHg m
* Imaging evidence suggests subject is not appropriate for mechanical thrombectomy
* Presence of intracardiac lead in right ventricle or atrium.
* Pacemaker or Implantable Cardioverter Defibrillator
* Presence of intracardiac thrombus
* Anaphylactic reaction to radiographic contrast agents that cannot be pre-treated
* Known right- to-left shunt,
* Known left ventricular ejection fraction ≤ 30%
* History of severe chronic pulmonary arterial hypertension
* History of underlying lung disease with oxygen dependence
* History of chest irradiation
* History of Heparin Induced Thrombocytopenia (HIT)
* Female who is pregnant or nursing
* Current participation in another investigational drug or device treatment study
* Life expectancy of \< 90 days as determined by the investigator
* Subjects who are intubated
The Effect of Injection Rate of Local Anesthetic in Caesarean Section

This randomized double-blind study aimed to compare the effects of two different subaracnoid lokal anesthetic injection rate in cesarean section. Totally 67 patients were included. The groups were compared in terms of maximum sensory and motor block level, time to reach T6 level, hemodynamic changes and nausea- vomiting saved.

A total of 67 patients 18-40 years undergoing cesarean, who were graded as American Society of Anesthesiologists physical status were randomly allocated into two groups, 120-sn injection time (n=34, Group F), 15-sn injection time (n=33, Group S). When the level of the sensory block achieve the T6 level the surgery was let to begin. The groups were compared in terms of hemodynamic values, use of efedrin, the time to achieve sensory block to the T6 level, maximum sensory block level and motor block level.

Eligibility Criteria:
Inclusion Criteria:

* Anesthesiologists risk score (ASA) I-II risk status
* Singleton pregnancy aged
* Between 18-40 years

Exclusion Criteria:

* Pregnant women with contraindications for spinal anesthesia;
* Placental anomaly;
* Hypertension
* Cardiac disease
* Vascular disease
* Hepatic disease
* Renal disease
* Hemodynamic instability
* Spinal deformity;
* Severe mental retardation
* Weight \< 50 kg or \>110 kg; height \< 140 cm or \> 180 cm
* Metabolic and Acid-base balance disorders
* Emergency patients